Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22558863 | 1.00 | EPHX2 (0.43) | EPHX2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16652200 | 0.87 | HDAC4 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16632037 | 0.84 | NPC1 (0.46) | DPP4 | |
| SCHEMBL22558920 | 0.84 | NPC1 (0.46) | DPP4 | |
| SCHEMBL22558945 | 0.84 | P2RX7 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL26154072 | 0.81 | P2RX7 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21795776 | 0.81 | CCR5 (0.39) | CYP3A4 | |
| SCHEMBL22585512 | 0.80 | EPHX2 (0.40) | EPHX2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22558726 | 0.78 | P2RX7 (0.40) | P2RX7HRH3KCNK3 | |
| SCHEMBL25586650 | 0.77 | DPP4 (0.49) | EPHX2DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057950-B1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-02 | — | — | EP | disclosed |
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-29 | — | — | US | disclosed |
| EP-3057950-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3057951-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9403816-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| WO-2015057205-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057203-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | RORC, RORB, RORA | EPHX2 1675/4885PSEN1 1872/4885PSEN2 2561/4885 |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | RORC, RORB, RORA | EPHX2 1857/4885PSEN1 1861/4885PSEN2 2723/4885 |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | EPHX2 1460/4885PSEN1 1894/4885PSEN2 2722/4885 |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | EPHX2 1384/4885PSEN1 2420/4885PSEN2 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.